



HAL
open science

Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death

Mathieu Chalouni, Stanislas Pol, Philippe Sogni, H el ene Fontaine, Karine Lacombe, Jean Marc-Lacombe, Laure Esterle, Celine Dorival, Marc Bourli ere, Firouz e Bani-Sadr, et al.

► **To cite this version:**

Mathieu Chalouni, Stanislas Pol, Philippe Sogni, H el ene Fontaine, Karine Lacombe, et al.. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death. *Journal of Hepatology*, 2021, 74 (1), pp.37 - 47. 10.1016/j.jhep.2020.08.008 . inserm-03332406v2

HAL Id: inserm-03332406

<https://inserm.hal.science/inserm-03332406v2>

Submitted on 30 Aug 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destin ee au d ep ot et  a la diffusion de documents scientifiques de niveau recherche, publi es ou non,  emanant des  tablissements d'enseignement et de recherche fran ais ou  trangers, des laboratoires publics ou priv es.

Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death

Mathieu Chalouni ¹, Stanislas Pol ², Philippe Sogni ², H el ene Fontaine ², Karine Lacombe ³⁻⁴, Jean-Marc-Lacombe ⁵, Laure Esterle ¹, Celine Dorival ³, Marc Bourli ere ⁶, Firouz e Bani-Sadr ⁷, Victor de Ledinghen ⁸⁻⁹, David Zucman ¹⁰, Dominique Larrey ¹¹, Dominique Salmon¹²⁻¹³, Fabrice Carrat * ^{3,14}, Linda Wittkop* ^{1,15} for the ANRS CO13 HEPAVIH and ANRS CO22 HEPATHER cohort study groups†

Affiliations

¹ Univ. Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, team MORPH3EUS, UMR 1219, CIC-EC 1401, F-3300 Bordeaux, France

² Universit e de Paris ; Assistance Publique - H opitaux de Paris, H opital Cochin, D epartement d'H epatoLOGIE ; INSERM U-1223 et ICD, Institut Pasteur, Paris, France

³ Sorbonne Universit e, INSERM, Institut Pierre Louis d'Epid emiologie et de Sant e Publique, IPLESP, F75012, Paris, France

⁴ APHP, H opital Saint-Antoine, Service de Maladies Infectieuses et Tropicales, Paris, F75012, France

⁵ INSERM Transfert, Paris, France

⁶ Department of Hepatology and Gastroenterology, H opital Saint Joseph, Marseille, France

⁷ Department of Internal Medicine, Clinical Immunology and Infectious Diseases, Robert Debr e Hospital, University Hospital, Reims, France

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

⁸ Centre Hospitalier Universitaire de Bordeaux, Hôpital Haut-Lévêque, Service d'Hépatologie, Bordeaux, France

⁹ INSERM U1053, Université de Bordeaux, Bordeaux, France

¹⁰ Hôpital Foch, service de médecine interne, Suresnes, France

¹¹ Service des maladies de l'appareil digestif, Hôpital Saint Eloi, IBR- Inserm Montpellier, France

¹² Université de Paris, Paris, France

¹³ Service Maladies infectieuses et tropicales, AP-HP, Hôpital Cochin Hôtel Dieu, Paris, France

¹⁴ AP-HP, Hôpital Saint-Antoine, Unité de Santé Publique, Paris, France

¹⁵ CHU de Bordeaux, Pôle de santé publique, F-33000 Bordeaux, France

* Equal contribution

† The ANRS CO13 HEPAVIH and ANRS CO22 HEPATHER cohort study groups are listed in the Acknowledgements

Corresponding author:

Linda Wittkop

Address: 146 rue Léo Saignat, CS61292, 33076 Bordeaux cedex, France

Telephone number: +33 (0)5 57 57 45 26

Fax number: 33 (0)5 56 24 00 81

Electronic mail address: linda.wittkop@u-bordeaux.fr

1
2 **Keywords:** HIV co-infection – DAA treatment – SVR – death – non-liver-related
3 cancers – liver-related events
4

5 **Word count:** 5982/6000
6

7
8 **Number of figures and tables:** 6
9

10
11 **Financial support:** This work was supported by the French national Agency for
12 Research on Aids and Viral Hepatitis (ANRS: France Recherche Nord & Sud Sida-HIV
13 Hépatites)
14
15
16
17

18
19 **Conflict of interest statement:**
20

21
22 Dr Stanislas Pol has received consulting and lecturing fees from Bristol-Myers Squibb,
23 Janssen, Gilead, Roche, MSD and Abbvie, Biotest, Shinogi, ViiV and grants from
24 Bristol-Myers Squibb, Gilead, Roche and MSD
25
26
27

28
29 Dr Philippe Sogni has received consulting and lecturing fees from AbbVie, Genfit,
30 Gilead, Janssen, Mayoly-Spindler, MSD
31
32
33

34
35 Dr Hélène Fontaine has received lecturing fees from Abbvie Gilead and MSD
36
37

38
39 Dr Dominique Salmon has received lecturing fees from Abbvie and Gilead
40
41

42 The other authors report no conflicts of interest.
43
44

45 **Authors' contributions**
46

47
48 Data collection: Stanislas Pol, Philippe Sogni, Hélène Fontaine, Karine Lacombe, Marc
49 Bourlière, Firouzé Bani-Sadr, Victor de Ledinghen, David Zucman, Dominique Larrey,
50 Dominique Salmon
51
52
53

54
55 Data curation: Jean-Marc-Lacombe, Laure Esterle, Celine Dorival
56
57

58
59 Formal analysis: Mathieu Chalouni, Linda Wittkop
60
61
62

1 Funding acquisition: Stanislas Pol, Philippe Sogni, H  l  ne Fontaine, Dominique
2 Salmon, Fabrice Carrat, Linda Wittkop
3

4
5 Methodology: Mathieu Chalouni, Fabrice Carrat, Linda Wittkop
6

7
8 Project Administration: Stanislas Pol, Philippe Sogni, H  l  ne Fontaine, Laure Esterle,
9 C  line Dorival, Dominique Salmon, Fabrice Carrat, Linda Wittkop
10

11
12 Writing – original draft: Mathieu Chalouni, Fabrice Carrat, Linda Wittkop
13

14
15 Writing – review & editing: Mathieu Chalouni, Stanislas Pol, Philippe Sogni, H  l  ne
16 Fontaine, Karine Lacombe, Jean-Marc-Lacombe, Laure Esterle, Celine Dorival, Marc
17 Bourli  re, Firouz   Bani-Sadr, Victor de Ledinghen, David Zucman, Dominique Larrey,
18 Dominique Salmon, Fabrice Carrat, Linda Wittkop
19
20
21
22
23
24
25
26

27 **Clinical trial number:**
28

29
30 ANRS CO13 HEPAVIH: NCT03324633
31

32
33 ANRS CO22 HEPATHER: ClinicalTrials.gov Identifier: NCT01953458
34
35

36
37 Data availability statement:
38

39
40 The ANRS CO13 HEPAVIH cohort is a French nationwide cohort sponsored by the
41 ANRS (France REcherche Nord&sud Sida-hiv Hepatites). Data is owned by ANRS and
42 there are also legal restrictions to share data publicly. Nonetheless, data can be
43 accessed upon demand to the scientific committee and the ANRS which can allow a
44 contractual access for collaboration purposes (laure.esterle@u-
45 bordeaux.fr/secretariat-clinique @anrs.fr). Applicants will be asked to complete a
46 Research Application Form specifying details for their planned study which will then be
47 reviewed by the ANRS CO13 Hepavih Scientific committee. The ANRS CO13 Hepavih
48 cohort is keen to promote collaboration among researchers and to see our unique co-
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

infected HIV-HCV patients database and biobank used in studies which meet our ethics and consenting process.

ABSTRACT

Background & Aims: Direct acting antivirals (DAA) lead to high sustained virological response (SVR) rates and decreased the risk of disease progression. We compared SVR rates and all-cause, liver- and non-liver-related deaths, liver-related events and non-liver-related cancers in HIV/HCV co-infected and HCV mono-infected participants from two French cohort studies after initiation of DAA treatment.

Methods: Up to 4 HCV mono-infected participants from the ANRS CO22 HEPATHER cohort were matched on age and sex to each HIV/HCV co-infected from the ANRS CO13 HEPAVIH cohort; both are nationwide, prospective, multicentre and observational. Participants initiated DAA between March 2014 and December 2017. Cox proportional Hazards models adjusted on age, sex, duration since HCV diagnosis, HCV transmission routes, HCV genotypes, cirrhosis, tobacco, alcohol consumption, and SVR (time dependent) were used.

Results: 592 HIV/HCV co-infected and 2049 HCV mono-infected participants were included. Median age was 53.3 years (interquartile range: 49.6-56.9) and 52.9 years (49.6 ; 56.7), and 1498 (73.1%) and 436 (73.6%) were men, and 159 (28.8%) and 793 (41.2%) were cirrhotic, respectively. SVR was observed in 92.9% and 94.6%, respectively. HIV co-infection was associated with higher risk of all-cause death (hazard ratio [HR] 1.93; 95% confidence interval [CI] 1.01-3.69), non-liver-related death (HR 2.84; 95%CI 1.27-6.36) and non-liver-related cancer (HR 3.26; 95%CI 1.50-7.08), but not with liver-related-death (HR 1.04; 95%CI 0.34-3.15) or liver-related events (HR 0.66; 95% CI 0.31-1.44).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Conclusion: After DAA treatment, HIV co-infected had similar SVR rates and risk of liver-related deaths and events compared to HCV mono-infected but higher risk of all-cause and non-liver-related deaths and non-liver-related cancers.


Abstract (259 words/275 words allowed)

Lay summary: We compared the risk of several clinical events in participants infected by human immunodeficiency virus and hepatitis C virus with those infected with hepatitis C virus alone, matched on age and sex, after treatment with contemporary direct acting antivirals. We found a higher risk of all-cause deaths, non-liver-related deaths and non-liver-related cancers in participants co-infected with the human immunodeficiency virus and hepatitis C virus, and no differences for the risk of liver-related deaths or events.

Highlights:

- Similar rates of SVR between HIV/HCV co-infected and HCV mono-infected participants
- Higher risk of all-cause deaths, non-liver-related deaths and cancers in HIV/HCV co-infected
- Similar risk of liver-related deaths and liver-related events in both populations

Graphical abstract:



INTRODUCTION

Hepatitis C virus (HCV) infection can lead to several liver-related (e.g liver decompensation, hepatocellular carcinoma [HCC], liver-related deaths)¹ and non-liver-related (e.g cardiovascular², non-liver cancer³, non-liver-related deaths⁴) events. Owing to similar transmission routes, HCV co-infection is common in patients infected with human immunodeficiency virus (HIV)⁵. Among HIV/HCV co-infected patients, risk factors for HCV-related events included detectable HIV viral load and low levels of CD4 counts^{1,6}. However, in the era of combination antiretroviral therapy risk, HIV- and HCV-related complications have decreased substantially^{7,8}. Direct-acting antivirals (DAA) lead to a sustained virological response (SVR; corresponding to HCV cure) in more than 90% of treated patients, both in HCV mono-infected patients and in HIV/HCV co-infected patients^{9,10}. HCV cure positively affects the course of HCV infection, both in HCV mono-infected and in HIV/HCV co-infected patients¹¹⁻¹⁷. Nevertheless, disease evolution after DAA treatment in HIV/HCV co-infected compared with HCV mono-infected patients has rarely been studied. Our main objectives were to compare SVR rates as well as risk of all-cause death, liver-related and non-liver-related deaths, liver-related events, and non-liver-related cancers, between HIV/HCV co-infected and HCV mono-infected after DAA initiation using data from two large, prospective, nationwide French cohort studies.

POPULATION AND METHODS

Patients

HIV/HCV co-infected participants from the ANRS CO13 HEPAVIH cohort (ClinicalTrials.gov Identifier: NCT03324633) and HCV mono-infected participants from

1 the ANRS CO22 HEPATHER cohort (ClinicalTrials.gov Identifier: NCT01953458) were
2 included. Both are multicentre, prospective, nationwide French cohort studies.
3

4 The ANRS CO13 HEPAVIH cohort started in 2005 and included HIV infected adults
5 with past or present HCV infection (2005-2010). From 2011, patients treated with first-
6 generation protease inhibitor HCV treatments, and from 2014 onwards patients treated
7 by any anti-HCV treatment, were eligible for enrolment. The main objectives of the
8 study are to characterize the natural history of HCV infection, to identify factors
9 associated with the development of liver complications, and to study the interactions
10 between HIV and HCV. From 2011 onwards, one of the main objectives was to study
11 the efficacy and safety of anti-HCV treatments in everyday clinical practice.
12
13

14 The ANRS CO22 HEPATHER cohort started in 2012 and included participants with
15 active or inactive hepatitis B virus or past or present HCV infection. The main objectives
16 of the study are to quantify the clinical efficacy and safety of new hepatitis treatments
17 in everyday clinical practice. The main exclusion criteria are HIV co-infection and
18 ongoing treatment for HCV at inclusion. We included only participants with chronic
19 HCV infection in the current analysis.
20
21

22 Follow-up visits are scheduled annually in both studies with supplementary visits
23 during anti-HCV treatment. Participants with cirrhosis in the ANRS CO13 HEPAVIH
24 cohort attend a supplementary visit every 6 months.
25
26

27 Written informed consent was obtained from all participants. Both studies followed the
28 ethical principles laid out by the World Medical Association (Declaration of Helsinki)
29 and were approved by an Institutional Review board (Comité de Protection des
30 Personnes (CPP) Ile de France III, Paris, France – ANRS CO13 HEPAVIH and ANRS
31 CO22 HEPATHER).
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Participants treated with DAA (with or without ribavirin and/or peg-interferon) between 1st March 2014 and 31st December 2017, who were not enrolled in a clinical trial, with no history of liver transplantation and with an available SVR status were included in the present analysis. Participants with previous liver-related events or non-liver-related cancers were excluded from the analyses that assessed the risk of these events. Baseline was defined as the date of DAA initiation.

For each co-infected participant, up to 4 HCV mono-infected participants were matched on age (± 3 years) at treatment initiation and sex.

Outcomes

The primary study outcomes were SVR rates and the time between baseline and the occurrence of a death from any cause, liver-related death, non-liver-related death, liver-related events, and non-liver-related cancers. Participants were classified as having reached SVR if they had undetectable HCV RNA at least 12 weeks after the end of DAA treatment. Participants with detectable HCV RNA at any time after the end of DAA treatment were classified as not having reached SVR. Cause of death was validated by an adjudication committee. Liver-related death was defined as that due to a liver-decompensation (liver encephalopathy, hepatorenal syndrome, oesophageal varices bleeding, oedemato-ascites decompensation, icterus), HCC or liver transplantation. Non-liver-related death was defined as death from any other cause. Liver-related events were defined as the occurrence of a liver decompensation, liver cancer (HCC or cholangiocarcinoma), liver transplantation or liver-related death. Non-liver-related cancer was defined as the occurrence of any non-liver-related cancer. Participants were followed until death (or a non-liver-related cancer or a liver-related event) or last follow-up visit, whichever came first.

Statistical analysis

1 SVR rates were compared between HIV/HCV co-infected and HCV mono-infected
2 patients according to DAA treatment (with/without ribavirin) overall, and stratified by
3
4 sex, cirrhosis, HCV genotype and prescribed HCV treatment duration (12 or 24 weeks).
5
6 Risk of all-cause death, liver-related death, non-liver-related death, liver-related events
7 and non-liver-related cancers between HIV/HCV co-infected and HCV mono-infected
8 patients was compared using cause-specific Cox proportional hazard models adjusted
9
10 on age at treatment initiation, sex, alcohol and tobacco consumption (both defined as
11
12 never, past or current), time since first HCV seropositivity, HCV transmission route
13
14 (drug use, sexual, transfusion, unknown, other), HCV genotype, SVR (as a time-
15
16 dependent variable) and cirrhosis. Cirrhosis was defined by cohort-specific algorithms.
17
18 For HIV/HCV co-infected participants, cirrhosis was defined as: an F4 classification on
19
20 the Metavir Score by liver biopsy at any time before DAA treatment; or liver-stiffness \geq
21
22 12.5 kPa (assessed by FibroScan) in a 3-month window before the initiation of DAA;
23
24 or a fibrosis-4 index value \geq 3.25 in a 3-month window before DAA initiation for
25
26 participants without an available liver-stiffness value. For HCV mono-infected
27
28 participants, cirrhosis was defined as a platelet count \leq 150,000/ml or a prothrombin
29
30 time \leq 70%. These criteria were validated in patients who had been classified as having
31
32 cirrhosis using other techniques \leq 1 year before, and up to 3 months after, the time of
33
34 evaluation¹⁵. Participants who died from a cause other than that studied were censured
35
36 at time of death.
37
38
39
40
41
42
43
44
45
46
47
48

49 Confounding factors were identified using directed acyclic graph (DAG) methodology.
50
51 We estimated predicted event probabilities over time for each event according to
52
53 parameters estimated by the Cox models described above for HIV/HCV co-infected
54
55 and HCV mono-infected participants. Therefore, we set all co-variables used in the
56
57 model as follows: mean observed age and time since first seropositivity, male sex,
58
59
60
61
62
63
64
65

1 infected by HCV genotype 1 due to drug use, non-consumers of alcohol and tobacco
2 and without cirrhosis. We compared participants with at least 1 missing datum for
3 variables included in the analysis to participants without missing data. Assuming data
4 were missing at random, missing data for explanatory variables included in the models
5 were imputed by multiple imputation methods using chained equations in R 3.6.2
6 software using mice package ¹⁸. Ten tables were generated by 10 iterations.
7 Quantitative variables were imputed using linear models and qualitative variables by
8 logistic regression or multinomial regression, as appropriate. Imputation models
9 included history of each event and of anti-HCV treatment, class and duration of DAA
10 treatment, platelets and albumin values, body mass index (BMI), and diabetes, in
11 addition to variables listed above and included in the multivariable models for the main
12 analyses. Normality of quantitative variables included in the imputation model was
13 checked graphically. As a sensitivity analysis, we studied the effect of HIV co-infection
14 on the risk of all-cause, liver-related and non-liver-related death, liver-related events
15 and non-liver-related cancer in complete case analysis. Cumulative incidences of each
16 event were estimated using the Fine and Gray methodology ¹⁹ in a sensitivity analysis.

38 **RESULTS**

39 **Baseline characteristics**

40 We included 592 HIV/HCV co-infected and 2049 HCV mono-infected participants.
41 Median age at treatment initiation was 52.9 (interquartile range [IQR]: 49.6-56.7) and
42 53.3 [IQR 49.6-56.9] years; and 73.6% and 73.1% were men (Table 1). Compared with
43 HCV mono-infected participants, HIV/HCV co-infected less frequently had cirrhosis
44 (28.8% vs 41.2%), had lower BMI (22.7 [IQR 20.2-25.3] vs 24.7 [IQR 22.3-27.5] kg/m²),
45 a higher proportion of current alcohol (53.4% vs 2.1%) and tobacco (60.6% vs 48.5%)
46 use, had HCV seropositivity for a longer time (18.0 [IQR 12.4-22.2] vs 14.5 [IQR 6.4-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

20.8] years), were less frequently infected by HCV genotype 1 (53.7% vs 63.6%) and more frequently infected by HCV genotype 4 (27.4% vs 15.0%).

Overall, 914 participants had at least one missing datum for variables included in the analysis models (145 in HIV/HCV co-infected and 769 in HCV mono-infected participants; Supplementary Table 1). Participants with missing data appeared to differ from participants without missing data for some characteristics in both populations (Supplementary Table 2).

SVR rates

Overall, 550 (92.9%) HIV/HCV co-infected and 1939 (94.6%) of HCV mono-infected reached SVR. In participants treated without ribavirin, SVR rates were 93.5% in HIV/HCV co-infected and 95.8% in HCV mono-infected participants whereas in participants treated with DAA and ribavirin, SVR rates were 91.0% in HIV/HCV co-infected and of 92.0% in HCV mono-infected participants (Table 2). HCV mono-infected cirrhotic participants appeared to have lower SVR rates than non-cirrhotic participants (respectively, 91.5% vs 97.7% in participants treated without ribavirin and 89.4% vs 95.8% in participants treated with DAA and ribavirin). Cirrhotic status did not seem to affect SVR rates in HIV/HCV co-infected participants (respectively, 93.0% vs 93.5% in participants treated without ribavirin and 91.1% and 92.0% in participants treated with DAA and ribavirin). SVR rates were inferior to 90% only in participants infected by HCV genotype 2 treated with DAA and ribavirin (83.3% in HIV/HCV co-infected and 80.0% in HCV mono-infected respectively).

Risk of death

All-cause death

1 After a median follow-up of 1.8 years [1.1 ; 2.5] in HIV/HCV co-infected and 2.3 years
2 [1.6 ; 3.1] in HCV mono-infected participants, 82 participants died. Cumulative
3 incidence of death is shown in Supplementary Fig. 1A. Twenty-six deaths were
4 observed in HIV/HCV co-infected participants (8 liver-related, 6 non-liver-related
5 cancer, 3 cardiovascular, 1 HIV and 8 other) and 56 in HCV mono-infected participants
6 (28 liver-related, 3 non-liver-related cancer, 4 cardiovascular and 21 other)
7 (Supplementary Table 3). Among the 26 HIV/HCV co-infected participants who died,
8 23 (88.5%) had reached SVR. Of the 56 HCV mono-infected participants who died, 46
9 (82.1%) had reached SVR.

10
11
12
13
14
15
16
17
18
19
20
21 After adjusting on confounding factors, HIV co-infection was associated with a higher
22 risk of all-cause death (HR 1.93, confidence interval at 95% (CI) 1.01-3.69) in HCV
23 infected participants after DAA treatment was observed (Table 3 and Fig. 1A). The
24 association between HIV co-infection and risk of all-cause death was similar in
25 complete case analysis (HR 1.99, 95% CI 1.04-3.83) (Supplementary Table 4).

26 27 28 29 30 31 32 33 34 35 ***Liver-related death***

36
37 In HIV/HCV co-infected participants, 8 liver-related-deaths (5 due to an HCC, 2 liver
38 decompensation, 1 liver transplantation) occurred after initiation of DAA therapy, of
39 which 6 were observed in cirrhotic participants, one in a non-cirrhotic participant and
40 one in a participant without available data on cirrhosis at initiation of DAA treatment.
41 Among HCV mono-infected participants, 28 liver-related deaths were observed (15
42 due to an HCC, 9 liver decompensation, 2 liver transplantation, 2 cholangiocarcinoma),
43 of which 26 were observed in cirrhotic participants (Supplementary Table 3 and
44 Supplementary Fig. 1B). Among the 8 liver-related deaths observed in HIV/HCV co-
45 infected, 6 occurred in those who reached SVR; 21 HCV mono-infected participants
46 died after reaching SVR.

1 After adjusting on confounding factors, no association between HIV co-infection and
2 the risk of liver-related death was found (HR 1.04; 95% CI 0.34-3.15) in HCV infected
3 participants treated with DAA (Table 3 and Fig. 1B). In complete case analysis, there
4 was also no effect of HIV co-infection on the risk of liver-related death after DAA
5 treatment (HR 1.09; 95% CI 0.35-3.35) (Supplementary Table 4).
6
7
8
9
10

11 ***Non-liver-related death***

12
13 Forty-six participants died from non-liver-related causes. In HIV/HCV co-infected
14 participants, 18 died from a non-liver-related cause (6 non-liver-related cancer, 3
15 cardiovascular, 1 HIV, 8 other) and 28 in HCV mono-infected participants (3 non-liver-
16 related cancer, 4 cardiovascular, 21 other) (Supplementary Table 3 and
17 Supplementary Fig. 1C). Seventeen HIV/HCV co-infected participants and 25 HCV
18 mono-infected participants died after reaching SVR.
19
20
21
22
23
24
25
26
27
28
29
30

31 After adjustment, HIV co-infection was associated with a higher risk of non-liver-related
32 death (HR 2.84 95% CI 1.27-6.36) compared with HCV infected participants treated
33 with DAA (Table 5 and Fig. 1C). In complete case analysis HIV co-infection was also
34 associated with an higher risk of non-liver-related death (HR: 2.92 [1.29 ; 6.60])
35 (Supplementary Table 4).
36
37
38
39
40
41
42
43
44

45 **Risk of liver-related events and non-liver-related cancers**

46 ***Liver-related events***

47
48 Eighty-three participants developed at least one liver-related event after the initiation
49 of DAA therapy: 17 HIV/HCV co-infected participants (8 liver-decompensation, 5 HCC,
50 4 liver-related deaths) and 66 HCV mono-infected (55 HCC, 10 liver decompensation,
51 1 liver-related death) (Supplementary Table 3 and Supplementary Fig. 2A). In
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 HIV/HCV co-infected participants, 11 participants developed a first liver-related event
2 after reaching SVR, 4 developed a liver-related event then reached SVR, and 2 liver-
3 related events occurred in participants who did not reach SVR. In HCV mono-infected
4 participants, 41 participants developed a liver-related event after reaching SVR, 11
5 before reaching SVR, and 14 participants developed a liver-related event and did not
6 reach SVR.
7
8

9 In adjusted analysis, HIV infection was not associated with risk of liver-related events
10 (HR 0.66; 95% CI 0.31-1.44) in HCV infected participants treated with DAA (Table 4
11 and Fig. 2A). Similar results were found in complete case analysis (HR = 0.40 [0.20 ;
12 0.81]).
13
14

15 **Non-liver-related cancers**

16 Non-liver-related cancers occurred in 50 participants; 22 in HIV/HCV co-infected
17 participants and 28 in HCV mono-infected participants. Among the non-liver-related
18 cancers observed in HIV/HCV co-infected participants, 2 were acquired immune
19 deficiency syndrome (AIDS) defining events (1 cervical cancer, 1 non-Hodgkin's
20 lymphoma) (Supplementary Table 3 and Supplementary Fig. 2B). Among HIV/HCV co-
21 infected participants, 15 developed a non-liver-related cancer after reaching SVR, 6
22 developed a non-liver-related cancer and then reached SVR, and 1 who did not reach
23 SVR developed a non-liver-related cancer. In HCV mono-infected participants, 26
24 developed a non-liver-related cancer after reaching SVR, 1 reached SVR after
25 developing a non-liver-related cancer, and 1 did not reach SVR and developed a non-
26 liver-related cancer.
27
28

29 After adjustment, HIV co-infection was significantly associated with a higher risk of
30 non-liver-related cancer (HR 3.26; 95% CI 1.50-7.08) compared with HCV infected
31 participants treated by DAA (Table 5 and Fig. 2B). In complete case analysis, HIV co-
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 infection was also associated with an higher risk of non-liver-related cancer (HR 3.26
2 [1.49 ; 7.10]) (Supplementary Table 5).
3
4

5 **DISCUSSION**

6
7

8
9 In a population of HCV infected participants treated with DAA, we observed similar
10 SVR rates between HIV/HCV co-infected and HCV mono-infected participants. After
11 adjustment on confounding factors, HIV co-infection was associated with an increased
12 risk of all-cause death after DAA initiation compared with HCV mono-infected
13 participants. This increased risk of all-cause death appears due to a higher risk of non-
14 liver-related death. Indeed, after adjustment on confounding factors, HIV co-infection
15 was strongly associated with the risk of non-liver-related death and was not associated
16 with the risk of liver-related death in participants infected by HCV. HIV/HCV co-infected
17 also had a higher risk than HCV mono-infected participants of developing non-liver-
18 related cancers after DAA initiation. Finally, we did not observe an association between
19 HIV co-infection and the risk of liver-related events, after DAA initiation in HCV infected
20 participants.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38
39 In this study, the SVR rates were high and were similar between HIV/HCV co-infected
40 and HCV mono-infected participants, overall and by subgroup. These results are in
41 agreement with previous report ²⁰⁻²². Neukam et al. reported a lower rate of SVR in an
42 HIV/HCV co-infected cohort compared to an HCV mono-infected cohort ²³.
43 Nevertheless, in their study, HIV co-infected were more frequently cirrhotic, infected
44 by HCV genotype 4 and had been exposed to anti-HCV therapy, which may explain
45 the difference in SVR rates observed between the two populations.
46
47
48
49
50
51
52
53
54
55

56 We compared the risk of all-cause death between HIV/HCV co-infected and HCV
57 mono-infected participants treated by DAA. Similar to the study by Salmon et al. ²⁴,
58
59
60
61
62
63
64
65

1 which included cirrhotic participants from the ANRS CO13 HEPAVIH cohort (the same
2 cohort as in the present study) and the ANRS CO12 CirVir cohort (a cohort including
3 Child A biopsy-proven cirrhosis), we observed a higher risk of all-cause death, linked
4 to a higher risk of non-liver-related death, in HIV co-infected compared to HCV mono-
5 infected participants.
6
7
8
9
10

11 In our study, the higher risk of all-cause death in HIV/HCV co-infected was essentially
12 due to a higher risk of non-liver-related death, whereas the risk of liver-related death
13 was similar between the two populations. To our knowledge, no other study has
14 compared the risk of non-liver-related death between HIV/HCV co-infected and HCV
15 mono-infected participants after DAA therapy. Salmon et al. also identified an higher
16 risk of non-liver-related death in HIV co-infected participants compared to HCV mono-
17 infected participants in a cirrhotic population that included both DAA-treated and
18 untreated participants ²⁴. From the 18 non-liver-related deaths observed in HIV/HCV
19 co-infected participants, only 1 was related to HIV. Several studies in HIV populations
20 highlight a high risk of non-AIDS defining cancers ^{25,26}. The higher risk of non-AIDS
21 death in HIV infected patients can be explained by chronic inflammation and immune
22 system dysregulation due to the HIV infection ^{25,27-29}, but also to high-risk behaviours
23 such as tobacco smoking and alcohol consumption ^{30,31}. High-risk behaviours were
24 observed in our study in HIV/HCV co-infected participants, with high rates of tobacco
25 (60.6%) and alcohol (53.4%) consumption. The higher risk of non-liver-related cancers
26 observed in HIV/HCV co-infected participants treated with DAA compared to HCV
27 mono-infected participants could not be explained by a higher incidence of AIDS
28 defining malignancies. Indeed, among the 22 non-liver-related cancers observed in
29 HIV/HCV co-infected participants, only 2 (non-Hodgkin's lymphoma and cervical
30 cancer) were AIDS-defining. As for non-liver-related death, the higher risk of non-liver-
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 related cancers in HIV/HCV co-infected participants could be partly explained by the
2 immunodepression induced by HIV. HIV induced immunodeficiency appears to
3
4 increase the risk of non-AIDS-defining cancers through the reduced control of
5
6 oncogenic virus infection and the reduced surveillance of malignant cells ³². The
7
8 chronic inflammation and coagulation defects induced by HIV could also explained the
9
10 higher risk of non-AIDS-defining cancers ³³. Finally, the higher risk of non-liver-related
11
12 cancers in HIV co-infected participants may also be explained by the higher
13
14 consumption of alcohol and tobacco in this population ^{30,31}.
15
16
17
18
19

20 Finally, we observed similar risks of liver-related death and liver-related events
21
22 between HIV/HCV co-infected and HCV mono-infected participants after DAA
23
24 treatment. In two previous studies, no differences were found between these
25
26 populations. Salmon et al. did not observe any difference in risk of liver
27
28 decompensation and HCC between HIV/HCV co-infected and HCV mono-infected
29
30 cirrhotic participants ²⁴. In another study comparing participants with advanced fibrosis,
31
32 co-infection by HIV was not associated with the risk of liver complications in HCV
33
34 participants who achieved SVR with DAA therapy ³⁴. Several reasons may explain
35
36 these results. First, owing to French recommendations, HCV mono-infected appeared
37
38 to be more frequently cirrhotic (41.2%) than HIV/HCV co-infected (28.8%). Second, in
39
40 this study, co-infected patients had an optimal immune virological status, demonstrated
41
42 by the median CD4 value was of 614.0 cells/mm³, 97.5% were treated by antiretroviral
43
44 therapy and 86.8% had an undetectable HIV viral load at DAA therapy initiation. These
45
46 factors are protective factors against the development of a liver-related event ^{1,6}. Third,
47
48 potentially better follow-up of HIV co-infected participants before the emergence of
49
50 DAA therapies, due to their HIV infection could have led to better control of HCV
51
52 infection and a decreased risk of liver-related events.
53
54
55
56
57
58
59
60
61
62
63
64
65

1 This study has several limitations. First, owing to recommendations for initiation of DAA
2 treatment, HCV mono-infected were more frequently cirrhotic than HIV/HCV co-
3 infected at treatment start-up. This may explain why we did not observe differences
4 between HIV/HCV co-infected and HCV mono-infected participants in the risk of liver-
5 related events and liver-related death. Even if all analysis were adjusted for cirrhosis,
6 residual confounding could persist. Second, as we included participants from two
7 different cohorts, data on events, specifically non-liver-related events, were not
8 necessarily collected in the same way, which may have led to misclassification. In
9 addition, a supplementary semiannual visit was scheduled for cirrhotic HIV/HCV co-
10 infected participants but not for cirrhotic HCV mono-infected participants. This
11 difference in follow-up could have led to earlier diagnosis of liver-related events and
12 non-liver-related cancers in cirrhotic HIV/HCV co-infected participants, and thus to an
13 overestimation of the effect of HIV co-infection on the risk of these events.
14 Nevertheless, the recommendation of semiannual hepatic ultrasonography in cirrhotic
15 HCV mono-infected participants was highly respected. In addition, event collection was
16 independent of follow-up. Thus, it seems unlikely that this supplementary semiannual
17 follow-up in HIV/HCV co-infected affected the estimated association between HIV co-
18 infection and the risk of events in HCV infected participants. Furthermore, we cannot
19 exclude closer follow-up of events in HIV/HCV co-infected compared to HCV mono-
20 infected participants due to their HIV infection, leading to overestimation of the risk of
21 non-liver-related cancers induced by HIV infection. However, both cohorts used similar
22 procedures to report all serious adverse events that occurred during the follow-up, with
23 extensive data-quality controls and monitoring. Third, participants with missing data for
24 SVR were excluded from the analysis. It can be expected that missing data for SVR
25 was related to higher risks of liver-related and non-liver-related events, potentially

1 leading to an underestimation of events in both cohorts. Fourth, to study the risk of
2 non-liver-related events in HIV/HCV co-infected participants treated with DAA a
3 comparison with HIV infected participants who were never infected by HCV, or with the
4 general population, may be more suitable. Finally, we matched on age and sex, which
5 led to the exclusion of 76 HIV/HCV co-infected participants (12.8% of the total
6 population). The reduced sample size could have led to a loss of statistical power.
7
8
9

10 This study also had several strengths. First, this study included more participants than
11 similar previous studies ^{24,34}. Second, the main confounding factors identified using
12 DAG methodology were included in our models, limiting the risk of confusion bias.
13
14 Third, both cohorts are prospective, nationwide French cohorts, underlying strict data
15 quality and monitoring rules, allowing for high-quality data. Finally, to our knowledge,
16 this is the first study comparing the risk of non-liver-related cancers between HIV/HCV
17 co-infected and HCV mono-infected participants after DAA therapy.
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 In conclusion, in a population of HIV/HCV co-infected participants with a controlled HIV
33 infection, no difference of SVR rates after DAA therapy was observed compared with
34 HCV mono-infected participants. After DAA therapy, we observed an almost twofold
35 higher risk of all-cause death, due to a higher risk of non-liver-related deaths in
36 HIV/HCV co-infected compared to HCV mono-infected participants. We also observed
37 a threefold higher risk of non-liver-related cancer in HIV/HCV co-infected compared to
38 HCV mono-infected participants, whereas no differences were observed in risk of liver-
39 related death or events after DAA therapy.
40
41
42
43
44
45
46
47
48
49
50
51

52 **ACKNOWLEDGMENTS**

53
54
55
56
57
58
59
60
61
62
63
64
65

1 Sophie K. Rushton-Smith (MedLink Healthcare Communications, London) provided
2 editorial assistance for the final version of the manuscript (limited to editing for style,
3
4 as well as figure and table editing) and was funded by the authors.
5
6
7
8
9

10 **For the ANRS CO13 HEPAVIH cohort study group**

11
12 Patients of the ANRS CO13 HEPAVIH Cohort

13 Scientific Committee of the ANRS CO13 HEPAVIH Study Group: D. Salmon (co-
14
15 Principal investigator), L. Wittkop (co-Principal Investigator & Methodologist), P. Sogni
16
17 (co-Principal Investigator), L. Esterle (project manager), P. Trimoulet, J. Izopet, L.
18
19 Serfaty, V. Paradis, B. Spire, P. Carrieri, M.A. Valantin, G. Pialoux, J. Chas, I. Poizot-
20
21 Martin, K. Barange, A. Naqvi, E. Rosenthal, A. Bicart-See, O. Bouchaud, A. Gervais,
22
23 C. Lascoux-Combe, C. Goujard, K. Lacombe, C. Duvivier, , D. Neau, P. Morlat, F. Bani-
24
25 Sadr, L. Meyer, F. Boufassa, , B. Autran, A.M. Roque, C. Solas, H. Fontaine, D.
26
27 Costagliola, L. Piroth, A. Simon, D. Zucman, F. Boué, P. Mialhes, E. Billaud, H.
28
29 Aumaître, D. Rey, G. Peytavin, V. Petrov-Sanchez, D. Lebrasseur-Longuet.
30
31
32
33
34
35
36
37
38

39 Clinical Centres (ward / participating physicians): APHP, Hôpitaux Universitaires Paris
40
41 Centre, Paris (Médecine Interne et Maladies Infectieuses : D. Salmon, R. Usubillaga;
42
43 Hépatogastro-entérologie : P. Sogni ; Anatomopathologie : B. Terris ; Virologie :P.
44
45 Tremeaux) ; APHP Pitié-Salpêtrière, Paris (Maladies Infectieuses et Tropicales : C.
46
47 Katlama, M.A. Valantin, H. Stitou ; Médecine Interne : A. Simon, P. Cacoub, S. Nafissa
48
49 ; Hépatogastro-entérologie : Y. Benhamou ; Anatomopathologie : F. Charlotte ;
50
51 Virologie : S. Fourati) ; APHM Sainte- Marguerite, Marseille (Service d'Immuno-
52
53 Hématologie Clinique : I. Poizot-Martin, O. Zaegel, H. Laroche ; Virologie : C. Tamalet)
54
55 ; APHP Tenon, Paris (Maladies Infectieuses et Tropicales : G. Pialoux, J. Chas;
56
57
58
59
60
61
62
63
64
65

1 Anatomopathologie : P. Callard, F. Bendjaballah ; Virologie : C. Amiel, C. Le
2 Pendeven) ; CHU Purpan, Toulouse (Maladies Infectieuses et Tropicales : B. Marchou
3 ; Médecine interne : L. Alric ; Hépatogastro-entérologie : K. Barange, S. Metivier ;
4 Anatomopathologie : J. Selves ; Virologie : F. Larroquette) ; CHU Archet, Nice
5 (Médecine Interne : E. Rosenthal ; Infectiologie : A. Naqvi, V. Rio ; Anatomopathologie
6 : J. Haudebourg, M.C. Saint-Paul ; Virologie : A. De Monte, V. Giordanengo, C.
7 Partouche) ; APHP Avicenne, Bobigny (Médecine Interne – Unité VIH : O. Bouchaud ;
8 Anatomopathologie : A. Martin, M. Ziol ; Virologie : Y. Baazia, V. Iwaka-Bande, A.
9 Gerber) ; Hôpital Joseph Ducuing, Toulouse (Médecine Interne : M. Uzan, A. Bicart-
10 See, D. Garipuy, M.J. Ferro-Collados ; Anatomopathologie : J. Selves ; Virologie : F.
11 Nicot) ; APHP Bichat – Claude-Bernard, Paris (Maladies Infectieuses : A. Gervais, Y.
12 Yazdanpanah; Anatomopathologie : H. Adle-Biassette ; Virologie : G. Alexandre,
13 Pharmacologie : G. Peytavin) ; APHP Saint-Louis, Paris (Maladies infectieuses : C.
14 Lascoux-Combe, J.M. Molina; Anatomopathologie : P. Bertheau; Virologie :M.L.
15 Chaix, C. Delaugerre, S. Maylin) ; APHP Saint-Antoine (Maladies Infectieuses et
16 Tropicales : K. Lacombe,; J. Krause, P.M. Girard, Anatomopathologie : D. Wendum,
17 P. Cervera, J. Adam ; Virologie : C. Viala) ; APHP, Hôpitaux Paris Sud, Bicêtre, Paris
18 (Maladies Infectieuses et Tropicales : D. Vittecocq ; Médecine Interne : C. Goujard,
19 Y. Quertainmont, E. Teicher; Virologie : C. Pallier) ; APHP Necker, Paris (Maladies
20 Infectieuses et Tropicales : O. Lortholary, C. Duvivier, C. Rouzaud, J. Lourenco, F.
21 Touam, C. Louisin : Virologie : V. Avettand-Fenoel, E. Gardiennet, A. Mélard) ; CHU
22 Bordeaux Hôpital Pellegrin, Bordeaux (Maladies Infectieuses et Tropicales : D. Neau,
23 A. Ochoa, E. Blanchard, S. Castet-Lafarie, C. Cazanave, D. Malvy, M. Dupon, H.
24 Dutronc, F. Dauchy, L. Lacaze-Buzy, A. Desclaux; Anatomopathologie : P. Bioulac-
25 Sage ; Virologie : P. Trimoulet, S. Reigadas) ; CHU Bordeaux Hôpital Saint-André,
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Bordeaux (Médecine Interne et Maladies Infectieuses : Médecine Interne et Maladies
2 Infectieuses : P. Morlat, D. Lacoste, F. Bonnet, N. Bernard, M. Hessamfar, J, F.
3
4 Paccalin, C. Martell, M. C. Pertusa, M. Vandenhende, P. Mercié, D. Malvy, T. Pistone,
5
6 M.C. Receveur, M. Méchain, P. Duffau, C Rivoisy, I. Faure, S. Caldato ; Anatomopathologie : P. Bioulac-Sage ; Virologie : P. Trimoulet, S. Reigadas, P. Bellecave, C.
7
8
9
10
11
12 Tumiotto) ; CHU Bordeaux Hôpital du Haut-Levêque, Bordeaux (Médecine Interne :
13
14 J.L. Pellegrin, J.F. Viallard, E. Lazzaro, C. Greib ; Anatomopathologie : P. Bioulac-
15
16 Sage ; Virologie : P. Trimoulet, S. Reigadas) ; Hôpital FOCH, Suresnes (Médecine
17
18 Interne : D. Zucman, C. Majerholc ; Virologie : M. Brollo, E. Farfour) ; APHP Antoine
19
20 Bécère, Clamart (Médecine Interne : F. Boué, J. Polo Devoto, I. Kansau, V. Chambrin,
21
22 C. Pignon, L. Berroukeche, R. Fior, V. Martinez, S. Abgrall, M. Favier ; Virologie : C.
23
24 Deback) ; CHU Henri Mondor, Créteil (Immunologie Clinique : Y. Lévy, S. Dominguez,
25
26 J.D. Lelièvre, A.S. Lascaux, G. Melica) ; CHU Nantes Hôpital Hôtel Dieu, Nantes
27
28 (Maladies Infectieuses et Tropicales : E. Billaud, F. Raffi, C. Allavena , V. Reliquet, D.
29
30 Boutoille, C. Biron; M. Lefebvre, N. Hall, S. Bouchez ; Virologie : A. Rodallec, L. Le
31
32 Guen, C. Hemon) ; Hôpital de la Croix Rouse, Lyon (Maladies Infectieuses et
33
34 Tropicales : P. Mialhes, D. Peyramond, C. Chidiac, F. Ader, F. Biron, A. Boibieux, L.
35
36 Cotte, T. Ferry, T. Perpoint, J. Koffi, F. Zoulim, F. Bailly, P. Lack, M. Maynard, S.
37
38 Radenne, M. Amiri, F Valour ; Hépatogastro-entérologie : J. Koffi, F. Zoulim, F. Bailly,
39
40 P. Lack, M. Maynard, S. Radenne, C. Augustin-Normand ; Virologie : C. Scholtes, T.T.
41
42 Le-Thi) ; CHU Dijon, Dijon (Département d'infectiologie :, L. Piroth, P. Chavanet M.
43
44 Duong Van Huyen, M. Buisson, A. Waldner-Combernoux, S. Mahy, R. Binois, A.L.
45
46 Simonet-Lann, D. Croisier-Bertin, A. Salmon Rousseau, C. Martins) ; CH Perpignan,
47
48 Perpignan (Maladies infectieuses et tropicales : H. Aumaître, Virologie : S. Galim) ;
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

clinique : F. Bani-Sadr, D. Lambert, Y Nguyen, J.L. Berger, M. Hentzien, Virologie : V. Brodard) ; CHRU Strasbourg (Le Trait d'Union : D Rey, M Partisani, ML Batard, C Cheneau, M Priester, C Bernard-Henry, E de Mautort, Virologie : P Gantner et S Fafi-Kremer)

Data collection: F. Roustant, P. Platterier, I. Kmiec, L. Traore, M-K. Youssouf, A. Benmammar, M-G. Tateo, S. Lepuil, Pomes ChloéV. Sicart-Payssan, , S. Anriamiandrisoa, C. Pomes, F. Touam, C. Louisin, M. Mole, P Catalan, M. Mebarki, A. Adda-Lievin, P. Thilbaut, Y. Ousidhoum, F.Z. Makhoukhi, O. Braik, R. Bayoud, C. Gatey, M.P. Pietri, V. Le Baut, R. Ben Rayana, F. Barret, C. Chesnel, D. Beniken, M. Pauchard, S. Akel, S. Caldato, T. Rojas-Rojas, C. Debreux, L. Chalal, J.Zelie, A. Soria, M. Cavellec, S. Breau, P. Fisher, C. Charles, D. Croisier-Bertin, S. Ogoudjobi, C. Brochier, V. Thoirain-Galvan, M. Le Cam.

Management, statistical analyses: P. Carrieri, M. Chalouni, V. Conte, L. Dequae-Merchadou, M. Desvallees, L. Esterle, C. Gilbert, S. Gillet, R. Knight, T. Lemboub, F. Marcellin, L. Michel, M. Mora, C. Protopopescu, P. Roux, B. Spire, S. Tezkratt, T. Barré, T. Rojas, M. Baudoin, M. Santos V. Di Beo, M.Nishimwe, , L Wittkop.

Funding: ANRS (France Recherche Nord & sud Sida-hiv Hépatites)

For the ANRS CO22 HEPATHER cohort study group

Funding

INSERM-ANRS (France REcherche Nord&sud Sida-vih Hepatites), ANR (Agence Nationale de la Recherche), DGS (Direction Générale de la Santé) and MSD, Janssen, Gilead, Abbvie, BMS, Roche.

ANRS-AFEF Hepather Study group

1 Laurent Alric, Delphine Bonnet, Virginie Payssan-Sicart, Chloe Pomes (CHU Purpan,
2 Toulouse, France), Fabien Zoulim, François Bailly, Marjolaine Beaudoin, Dominique
3 Giboz, Kerstin Hartig-Lavie, Marianne Maynard (Hospices Civils de Lyon, Lyon,
4 France), François Raffi, Eric Billaud, David Boutoille, Morane Cavellec, Marjorie
5 Cheraud-Carpentier (Hôpital Hôtel-Dieu, Nantes, France), Paul Cales, Isabelle Hubert,
6 Pierre Goepfert, Adrien Lannes, Françoise Lunel, Jérôme Boursier (CHU Angers,
7 Angers, France), Tarik Asselah, Nathalie Boyer, Nathalie Giully, Corinne Castelnau,
8 Giovanna Scoazec (Hôpital Beaujon, Clichy, France), Stanislas Pol, Hélène Fontaine,
9 Aziza Chibah, Sylvie Keser, Karim Bonardi, Anaïs Vallet-Pichard, Philippe Sogni
10 (Hôpital Cochin, Paris, France), Victor De Ledinghen, Juliette Foucher, Jean-Baptiste
11 Hiriart, Amandine Legendre, Faiza Chermak, Marie Irlès-Depé (Hôpital Haut-Lévêque,
12 Pessac, Bordeaux, France), Marc Bourlière, Si Nafa Si Ahmed, Christelle Ansaldi,
13 Nisserine Ben Amara, , Valérie Oules, Jacqueline Dunette (Hôpital Saint Joseph,
14 Marseille, France), Albert Tran, Rodolphe Anty, Eve Gelsi, Régine Truchi (CHU de
15 Nice, Nice, France), Dominique Thabut, Elena Luckina, Nadia Messaoudi, Joseph
16 Moussali (Hôpital de la Pitié Salpêtrière, Paris, France), Xavier Causse, Barbara De
17 Dieuleveult, Héloïse Goin, Damien Labarrière, Pascal Potier, Si Nafa Si Ahmed (CHR
18 La Source, Orléans, France), Nathalie Ganne, Véronique Grando-Lemaire, Pierre
19 Nahon, Séverine Brulé, Rym Monard (Hôpital Jean Verdier, Bondy, France),
20 Dominique Guyader, Caroline Jezequel, Audrey Brener, Anne Laligant, Aline Rabot,
21 Isabelle Renard (CHU Rennes, Rennes, France), François Habersetzer, Thomas F.
22 Baumert, Michel Doffoel, Catherine Mutter, Pauline Simo-Noumbissie, Esma Razi
23 (Hôpitaux Universitaires de Strasbourg, Strasbourg, France), Jean-Pierre Bronowicki,
24 Hélène Barraud, Mouni Bensenane, Abdelbasset Nani, Sarah Hassani-Nani, Marie-
25 Albertine Bernard (CHU de Nancy, Nancy, France), Dominique Larrey, Georges-

1 Philippe Pageaux, Michael Bismuth, Ludovic Caillo, Stéphanie Faure, Marie Pierre
2 Ripault (Hôpital Saint Eloi, Montpellier, France), Sophie Métivier, Christophe Bureau,
3
4 Sarah Launay, Jean Marie Peron, Marie Angèle Robic, Léa Tarallo (CHU Purpan,
5
6 Toulouse, France), Thomas Decaens, Marine Faure, Bruno Froissart, Marie-Noelle
7
8 Hilleret, Jean-Pierre Zarski (CHU de Grenoble, Grenoble, France), Ghassan Riachi,
9
10 Odile Gorla, Victorien Grard, Hélène Montialoux (CHU Charles Nicolle, Rouen,
11
12 France), Vincent Leroy, Muriel François, Christian Ouedraogo, Christelle Pauleau,
13
14 Anne Varault (Hôpital Henri Mondor, Créteil, France), Olivier Chazouillères, Tony
15
16 Andreani, Bénédicte Angoulevant, Azeline Chevance, Lawrence Serfaty (Hôpital
17
18 Saint-Antoine, Paris, France), Didier Samuel, Teresa Antonini, Audrey Coilly, Jean-
19
20 Charles Duclos Vallée, Mariagrazia Tateo (Hôpital Paul Brousse, Villejuif, France),
21
22 Armand Abergel, Corinne Bonny, Chanteranne Brigitte, Géraldine Lamblin, Léon Muti
23
24 (Hôpital Estaing, Clermont-Ferrand, France), Claire Geist, Abdenour Babouri, Virginie
25
26 Filipe (Centre Hospitalier Régional, Metz, France), Isabelle Rosa, Camille Barrault,
27
28 Laurent Costes, Hervé Hagège, Soraya Merbah (Centre Hospitalier Intercommunal,
29
30 Créteil, France), Véronique Loustaud-Ratti, Paul Carrier, Maryline Debette-Gratien,
31
32 Jérémie Jacques (CHU Limoges, Limoges, France), Philippe Mathurin, Guillaume
33
34 Lassailly, Florent Artu, Valérie Canva, Sébastien Dharancy, Alexandre Louvet (CHRU
35
36 Claude Huriez, Lille, France), Anne Minello, Marianne Latournerie, Marc Bardou,
37
38 Thomas Mouillot (Dijon University Hospital, Dijon, France), Louis D'Alteroche, Yannick
39
40 Bacq, Didier Barbereau, Charlotte Nicolas (CHU Trousseau, 37044 Tours, France),
41
42 Jérôme Gournay, Caroline Chevalier, Isabelle Archambeaud, Sarah Habes (CHU de
43
44 Nantes, Nantes, France), Isabelle Portal, Nisserine Ben Amara, Danièle Botta-
45
46 Fridlund, (CHU Timone, Marseille, France), Moana Gellu-Simeon, Eric Saillard, Marie-
47
48 Josée Lafrance, (CHU de Pointe-à-Pitre, Pointe-à-Pitre, Guadeloupe).
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 Scientific Committee:

3
4 - Voting members :

5
6
7 Marc Bourlière (Hôpital St Joseph, Marseille), Jérôme Boursier (CHU Angers, Angers,
8
9 France), Fabrice Carrat (Scientific Coordinator, Hôpital Saint-Antoine, Paris, France),
10
11 Patrizia Carrieri (INSERM U912, Marseille, France), Elisabeth Delarocque-Astagneau
12
13 (Inserm UMR1181, Paris), Victor De Ledinghen (Hôpital Haut-Lévêque, Pessac,
14
15 Bordeaux, France), Céline Dorival (UPMC & INSERM U1136, Paris, France), Hélène
16
17 Fontaine (Hôpital Cochin, Paris, France), Slim Fourati (Hôpital Henri Mondor, Créteil,
18
19 France), Chantal Housset (Inserm UMR-S938 1 IFR65, Paris), Dominique Larrey
20
21 (Hôpital Saint Eloi, Montpellier, France), Pierre Nahon (Hôpital Jean Verdier, Bondy,
22
23 France), Georges-Philippe Pageaux (Hôpital Saint Eloi, Montpellier, France),
24
25 Ventzislava Petrov-Sanchez (ANRS, Paris, France), Stanislas Pol (Principal
26
27 Investigator, Hôpital Cochin, Paris, France), Sophie Vaux (Agence Nationale de Santé
28
29 Publique, Saint Maurice, France), Linda Wittkop (ISPED-INSERM U1219, Bordeaux,
30
31 France), Fabien Zoulim (Hospices Civils de Lyon, Lyon, France), Jessica Zucman-
32
33 Rossi (Inserm U674/1162, Paris).

34
35
36
37
38
39 - Non voting members:

40
41
42
43 Marianne L'hennaff (ARCAT-TRT-5-CHV, France), Michèle Sizorn (SOS hépatites,
44
45 France); one representative of INSERM-ANRS Pharmacovigilance team, Paris,
46
47 France (Lena Wadouachi, Alpha Diallo), Carole Cagnot (INSERM-ANRS, Paris,
48
49 France), one member of Inserm Transfert, Paris, France (Alice Bousselet, Mireille
50
51 Caralp), and one representative of each pharmaceutical company (MSD, Gilead,
52
53 Abbvie).
54
55
56
57
58
59
60
61
62
63
64
65

Sponsor: Alpha Diallo, Carole Cagnot, Lena Wadouachi (INSERM-ANRS, Paris, France), Ventzi Petrov-Sanchez (coordinator).

Methodology and Coordinating Centre: Douae Ammour, Loubna Ayour, Jaouad Benhida, Fabrice Carrat (coordinator), Frederic Chau, Céline Dorival, Isabelle Goderel, Warda Hadi, Clovis Lusivika-Nzinga, Grégory Pannetier, François Pinot, Odile Stahl, François Téloulé (Sorbonne Université & INSERM U1136, Paris, France).

REFERENCES

1. Westbrook RH, Dusheiko G. Natural history of hepatitis C. *J Hepatol*. 2014 Nov;61(1 Suppl):S58-68.
2. Petta S, Di Marco V, Bruno S, Enea M, Calvaruso V, Boccaccio V, et al. Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model. *Liver Int Off J Int Assoc Study Liver*. 2016 Dec;36(12):1765–73.
3. Allison RD, Tong X, Moorman AC, Ly KN, Rupp L, Xu F, et al. Incidence of Cancer and Cancer-related Mortality Among Persons with Chronic Hepatitis C Infection, 2006–2010. *J Hepatol*. 2015 Oct;63(4):822–8.
4. Lee M-H, Yang H-I, Lu S-N, Jen C-L, You S-L, Wang L-Y, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. *J Infect Dis*. 2012 Aug 15;206(4):469–77.
5. Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. *Lancet Infect Dis*. 2016 Jul;16(7):797–808.
6. Gjørde LI, Shepherd L, Jablonowska E, Lazzarin A, Rougemont M, Darling K, et al. Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2016 Sep 15;63(6):821–9.
7. Qurishi N, Kreuzberg C, Lüchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. *Lancet Lond Engl*. 2003 Nov 22;362(9397):1708–13.
8. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N Engl J Med*. 1998 Mar 26;338(13):853–60.
9. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. *N Engl J Med*. 2015 Aug 20;373(8):705–13.
10. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. *Hepatology*. 2015 Apr 1;61(4):1127–35.
11. Bang CS, Song IH. Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis. *BMC Gastroenterol*. 2017 Apr 4;17(1):46.
12. Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. *Gastroenterology*. 2017 Jan;152(1):142-156.e2.
13. Tada T, Kumada T, Toyoda H, Kiriya S, Tanikawa M, Hisanaga Y, et al. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis. *J Gastroenterol Hepatol*. 2017 Mar;32(3):687–94.
14. Bruno S, Di Marco V, Iavarone M, Roffi L, Crosignani A, Calvaruso V, et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. *J*

Hepatol. 2016 Jun;64(6):1217–23.

15. Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. *Lancet Lond Engl.* 2019 Apr 6;393(10179):1453–64.
16. Loko M-A, Bani-Sadr F, Valantin M-A, Lascoux-Combe C, Fontaine H, Bonnard P, et al. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort. *Antivir Ther.* 2012;17(7):1335–43.
17. ANRS CO13 HEPAVIH Cohort. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients. *AIDS Lond Engl.* 2015 Sep 10;29(14):1821–30.
18. Buuren S van, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. *J Stat Softw.* 2011 Dec 12;45(1):1–67.
19. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. *J Am Stat Assoc.* 1999 Jun 1;94(446):496–509.
20. Bruno G, Saracino A, Scudeller L, Fabrizio C, Dell'Acqua R, Milano E, et al. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? *Int J Infect Dis IJID Off Publ Int Soc Infect Dis.* 2017 Sep;62:64–71.
21. Bischoff J, Mauss S, Cordes C, Lutz T, Scholten S, Moll A, et al. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? *HIV Med.* 2018;19(4):299–307.
22. Milazzo L, Lai A, Calvi E, Ronzi P, Micheli V, Binda F, et al. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy. *HIV Med.* 2017;18(4):284–91.
23. Neukam K, Morano-Amado LE, Rivero-Juárez A, Mancebo M, Granados R, Téllez F, et al. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study. *HIV Clin Trials.* 2017;18(3):126–34.
24. Salmon-Ceron D, Nahon P, Layese R, Bourcier V, Sogni P, Bani-Sadr F, et al. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients. *Hepatol Baltim Md.* 2019 Sep;70(3):939–54.
25. Franzetti M, Ricci E, Bonfanti P. The Pattern of Non-AIDS-defining Cancers in the HIV Population: Epidemiology, Risk Factors and Prognosis. A Review. *Curr HIV Res.* 2019;17(1):1–12.
26. Billa O, Chalouni M, Salmon D, Poizot-Martin I, Gilbert C, Katlama C, et al. Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort. *PLoS One.* 2018;13(12):e0208657.
27. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. *Lancet Lond Engl.* 2007 Jul 7;370(9581):59–67.
28. Franzetti M, Adorni F, Parravicini C, Vergani B, Antinori S, Milazzo L, et al. Trends and predictors of non-AIDS-defining cancers in men and women with HIV infection: a single-institution

retrospective study before and after the introduction of HAART. *J Acquir Immune Defic Syndr* 1999. 2013 Apr 1;62(4):414–20.

29. Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, Scherzer R, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. *J Acquir Immune Defic Syndr* 1999. 2010 Nov;55(3):316–22.

30. Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, et al. HIV infection and the risk of cancers with and without a known infectious cause. *AIDS Lond Engl*. 2009 Nov 13;23(17):2337–45.

31. Santos ME, Protopopescu C, Sogni P, Yaya I, Piroth L, Bailly F, et al. HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort). *AIDS Behav*. 2020 Apr;24(4):1069–84.

32. Borges AH, Dubrow R, Silverberg MJ. Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk. *Curr Opin HIV AIDS*. 2014 Jan;9(1):34–40.

33. Borges ÁH, Silverberg MJ, Wentworth D, Grulich AE, Fätkenheuer G, Mitsuyasu R, et al. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. *AIDS Lond Engl*. 2013 Jun 1;27(9):1433–41.

34. Corma-Gómez A, Morano L, Téllez F, Rivero-Juárez A, Real LM, Alados JC, et al. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals. *AIDS Lond Engl*. 2019 01;33(7):1167–74.

35. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. *J Hepatol*. 2017 Sep 5;

36. Butt AA, Yan P, Simon TG, Abou-Samra A-B. Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2017 Sep 15;65(6):1006–11.

Table 1. Characteristics at time of DAA initiation according to HIV co-infection in HCV infected participants from the ANRS CO13 HEPAVIH and ANRS CO22 HEPATHER cohorts.

Characteristics	HIV ⁺ /HCV* co-infected (n = 592)		HCV* mono-infected (n = 2049)	
	N	Median [IQR*] or n (%)	N	Median [IQR*] or n (%)
Age (years)	592	52.9 [49.6 ; 56.7]	2049	53.3 [49.6 ; 56.9]
Men	592	436 (73.6%)	2049	1498 (73.1%)
BMI^A (kg/m²)	586	22.7 [20.2 ; 25.3]	2042	24.7 [22.3 ; 27.5]
< 18.5		61 (10.4%)		53 (2.6%)
18.5 ; 25.0[370 (63.1%)		1043 (51.1%)
25.0 ; 30.0[122 (20.8%)		693 (33.9%)
≥ 30		33 (5.6%)		253 (12.4%)
Alcohol consumption	581		1375	
Never		134 (23.1%)		832 (60.5%)
Past		137 (23.6%)		514 (37.4%)
Current		310 (53.4%)		29 (2.1%)
Tobacco consumption	578		2045	
Never		98 (17.0%)		504 (24.6%)
Past		130 (22.5%)		550 (26.9%)
Current		350 (60.6%)		991 (48.5%)
Diabetes	592	56 (9.5%)	2049	228 (11.1%)
Time since first HCV* seropositivity (years)	566	18.0 [12.4. ; 22.2]	2049	14.5 [6.4 ; 20.8]
HCV* contamination routes	520		2037	
Drug use		325 (62.5%)		765 (37.6%)
Sexual		92 (17.7%)		21 (1.0%)
Transfusion		40 (7.7%)		476 (23.4%)
Unknown		57 (11.0%)		465 (22.8%)

Other		6 (1.2%)		310 (15.2%)
HCV* genotype	583		2034	
1				
2		313 (53.7%)		1293 (63.6%)
3		22 (3.8%)		80 (3.9%)
4		85 (14.6%)		334 (16.4%)
5		160 (27.4%)		306 (15.0%)
6		3 (0.5%)		21 (1.0%)
7				
8				
9				
10				
11				
12				
13				
14				
History of anti-HCV* treatment	592	343 (57.9%)	1927	1072 (55.7%)
Cirrhosis	553	159 (28.8%)	1927	793 (41.2%)
Platelets (10^3 cells/mm³)	574	179.0 [138.0 ; 222.0]	2029	185.0 [138.0 ; 233.0]
Albumin (g/L)	469	42.0 [39.0 ; 44.2]	1905	42.0 [38.8 ; 44.7]
Time since first HIV[‡] seropositivity (years)	590	24.7 [18.8 ; 28.2]	-	-
CD4 count (cells/mm³)	587	614.0 [411.0 ; 861.0]	-	-
≥ 500		375 (63.9%)		-
200 ; 500]		175 (29.8%)		-
≤ 200		37 (6.3%)		-
Undetectable HIV[‡] viral load	562	488 (86.8%)	-	-
ARV^Ψ intake	592	577 (97.5%)	-	-
Time since ARV^Ψ initiation (years)	577	17.6 [10.9 ; 20.3]	-	-

* Hepatitis C virus, ‡ Human Immunodeficiency virus, ¥ Interquartile range, Δ Body mass index, Ψ Antiretroviral

Table 2. Sustained virological response according to HIV co-infection and use of ribavirin in HCV infected participants from the ANRS CO13 HEPAVIH and ANRS CO22 HEPATHER cohorts

Characteristics	HIV [‡] /HCV* co-infected (<i>n</i> = 482)				HCV* mono-infected (<i>n</i> = 1736)			
	DAA**		DAA** + RBV ^ψ		DAA**		DAA** + RBV ^ψ	
	N	n (%)	N	n (%)	N	n (%)	N	n (%)
Overall	447	418 (93.5%)	145	132 (91.0%)	1411	1352 (95.8%)	638	587 (92.0%)
Men	324	314 (93.8%)	112	102 (91.1%)	988	945 (95.6%)	510	468 (91.8%)
Women	123	114 (92.7%)	33	30 (90.9%)	423	407 (96.2%)	128	119 (93.0%)
Cirrhotic	114	106 (93.0%)	45	41 (91.1%)	434	397 (91.5%)	359	321 (89.4%)
Non-cirrhotic	306	286 (93.5%)	88	81 (92.0%)	897	876 (97.7%)	237	227 (95.8%)
Treatment naïve	213	198 (93.0%)	36	32 (88.9%)	645	630 (97.7%)	209	196 (93.8%)
Treatment experienced	234	220 (94.0%)	109	100 (91.7%)	691	650 (94.1%)	381	348 (91.3%)
Genotype 1	258	243 (94.2%)	55	51 (92.7%)	1001	971 (97.0%)	292	274 (93.8%)
Genotype 2	10	10 (100.0%)	12	10 (83.3%) [§]	25	25 (100.0%)	55	44 (80.0%) ^Δ
Genotype 3	43	41 (95.3%)	42	39 (92.9%)	168	150 (89.3%)	166	152 (91.6%)
Genotype 4	126	115 (91.3%)	34	30 (88.1%)	186	176 (94.6%)	120	112 (93.3%)
Genotype 5/6/7	3	3 (100.0%)	0	-	17	17 (100.0%)	4	4 (100.0%)
Treated for 12 weeks	338	312 (92.3%)	82	74 (90.2%)	1181	1138 (96.4%)	437	401 (91.8%)
Treated for 24 weeks	109	106 (97.2%)	63	58 (92.1%)	230	214 (93.0%)	201	186 (92.5%)
Undetectable HIV[‡] viral load	362	342 (94.5%)	126	115 (91.3%)	-	-	-	-
Detectable HIV[‡] viral load	62	55 (88.7%)	12	11 (91.7%)	-	-	-	-

* Hepatitis C virus, [‡]Human immunodeficiency virus, ** Direct acting antiviral, ^ψ Ribavirin, [§] Participants treated by Sofosbuvir + interferon (1), or Sofosbuvir (53) or Sofosbuvir + Simeprevir (1), ^Δ Participants treated by Sofosbuvir (11) or Sofosbuvir + Daclatasvir (1)

Table 3. Association between HIV co-infection and risk of all-cause, liver-related and non-liver-related death in HCV infected participants from the ANRS CO13 HEPAVIH and ANRS CO22 HEPATHER cohorts.

	All-cause death		Liver-related death		Non-liver-related death	
	HR* [CI95%**]	p-value	HR* [CI95%**]	p-value	HR* [CI95%**]	p-value
HCV[‡] mono-infected	Ref	0.05	ref	0.95	ref	0.01
HIV^Ψ/HCV[‡] co-infected	1.93 [1.01 ; 3.69]		1.04 [0.34 ; 3.15]		2.84 [1.27 ; 6.36]	

* Hazard ratio, ** Confidence interval at 95%, [‡]Hepatitis C virus, ^Ψ Human immunodeficiency virus

Adjusted on age, sex, time since first HCV seropositivity, HCV transmission routes, HCV genotype, cirrhosis, time dependent SVR, alcohol consumption and tobacco consumption



Table 4. Association between HIV co-infection and risk of liver-related events and non-liver-related cancers in HCV infected participants from the ANRS CO13 HEPAVIH and ANRS CO22 HEPATHER cohorts.

	Liver-related events			Non-liver-related cancer		
	HR*	CI95%**	p-value	HR*	CI95%**	p-value
HCV[‡] mono-infected	ref	-	0.30	ref	-	< 0.01
HIV^Ψ/HCV[‡] co-infected	0.66	[0.31 ; 1.44]		3.26	[1.50 ; 7.08]	

* Hazard ratio, confidence interval at 95%, [‡]Hepatitis C virus, ^ΨHuman Immunodeficiency virus

Adjusted on age, sex, time since first HCV seropositivity, HCV transmission routes, HCV genotype, cirrhosis, time dependent SVR, alcohol consumption and tobacco consumption

Fig. 1. Predicted probability over time of death according to HIV co-infection. (A) Predicted probability of all-cause death. **(B)** Predicted probability of liver-related death. **(C)** Predicted probability of non-liver-related death. Estimates reflect the probability of an event for 53-year-old, male participants infected by HCV genotype 1 due to drug use, seropositive for HCV for 15 years, non-alcohol, non tobacco consumer, without cirrhosis at time of DAA initiation. Estimated in participants from the ANRS CO13 HEPAVIH and ANRS CO22 HEPATHER cohorts, treated by DAA between March 2014 and December 2017




Patients at risk:

HIV/HCV	592	514	363	214
HCV	2047	1827	1419	967

Patients at risk:

HIV/HCV	592	514	363	214
HCV	2047	1827	1419	967




Patients at risk:

HIV/HCV	592	514	363	214
HCV	2047	1827	1419	967

Fig. 2. Predicted probability over time of events according to HIV co-infection.

(A) Predicted probability over-time of liver-related-events. (B) Predicted probability over-time of non-liver-related cancers. Estimates reflect the probability of an event for 53-year-old, male participants infected by HCV genotype 1 due to drug use, seropositive for HCV for 15 years, non-alcohol, non tobacco consumer, without cirrhosis at time of DAA initiation. Estimated in participants from the ANRS CO13 HEPAVIH and ANRS CO22 HEPATHER cohorts treated by DAA between March 2014 and December 2017.




Patients at risk:

HIV/HCV	575	493	344	199
HCV	1848	1611	1236	807

Patients at risk:

HIV/HCV	548	459	335	189
HCV	2016	1787	1377	934


Figure



Patients at risk:

HIV/HCV	592	514	363	214
HCV	2047	1827	1419	967


(A)



Patients at risk:

HIV/HCV	592	514	363	214
HCV	2047	1827	1419	967

(B)




Patients at risk:


HIV/HCV	592	514	363	214
HCV	2047	1827	1419	967

(C)

Figure



(A)



(B)


Patients at risk:

HIV/HCV	575	493	344	199
HCV	1848	1611	1236	807

Patients at risk:

HIV/HCV	548	459	335	189
HCV	2016	1787	1377	934

Impact of HIV co-infection on mortality and morbidity after DAA in HCV-infected participants

HCV infected treated by DAA  2641

Treated outside a clinical trial

Without history of liver transplantation

Available SVR status

HCV mono-infected

 2049

ANRS CO22
HEPATHER cohort

94.6%
of SVR

HIV/HCV co-infected

 592

ANRS CO13
HEPAVIH cohort

92.9%
of SVR

Up to 4 HCV mono-infected matched on age and sex to each HIV/HCV co-infected

Increased all-cause mortality



2 times higher risk in HIV/HCV co-infected

Increased non-liver-related mortality



3 times higher risk in HIV/HCV co-infected

Similar liver-related mortality



No difference between the two populations

HIV increased risk of overall mortality, non-liver-related mortality but not of liver-mortality in HCV-infected patients

Highlights:

- Similar rates of SVR between HIV/HCV co-infected and HCV mono-infected participants
- Higher risk of all-cause deaths, non-liver-related deaths and cancers in HIV/HCV co-infected
- Similar risk of liver-related deaths and liver-related events in both populations



[Click here to access/download](#)

Supplementary material

SUPPLEMENTARY MATERIALS_2.0.docx

